What the business is, and whether it's a good one at a fair price.
Operates across three reported business areas: Pharmaceuticals, Agro, and Plastic polymer films, with consolidated FY26 revenue of Rs. 115.91 crore and a net profit of Rs. 0.39 crore. The June 2026 filings disclose a non-binding strategic cooperation and technology transfer agreement to set up a plastic film manufacturing project in the Kyrgyz Republic, covering technology transfer, machinery sourcing, government liaison, investment facilitation, skill development, import-export support, and financing assistance; no monetary consideration has been recorded and a joint venture is only contemplated later. The cost shape is unusual for a manufacturer: materials are shown as 0.0% of revenue, with employee cost at 0.4% and other operating expenses at 0.2% of revenue, suggesting the reported revenue is largely a pass-through or trading activity rather than in-house manufacturing. Operating cash flow on a standalone basis was negative Rs. 121.35 Lacs in FY26, even as the company moved from a loss of Rs. 69.51 Lacs in FY25 to a profit of Rs. 37.50 Lacs on a standalone revenue jump from Rs. 294.28 Lacs to Rs. 11,223.10 Lacs. The company is a micro-cap BSE-listed entity (paid-up equity Rs. 4 crore, net worth Rs. 4.02 crore) headquartered in Ahmedabad, with two promoters holding shares and no encumbrance declared on them.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from Vivanza Biosciences Limited's filed financials and exchange disclosures
Vivanza Biosciences Limited is a Pharmaceuticals & Biotechnology company listed on BSE.
Yes. Over the trailing twelve months Vivanza Biosciences Limited reported a net profit of ₹0 Cr on revenue of ₹116 Cr.
Not in the latest reported year — Vivanza Biosciences Limited's dividend payout for FY26 was nil.
No. Debt stands at 2.34× equity, and it carries net debt of ₹10 Cr. That is lower than 2% of its 171 Pharmaceuticals peers.
On trailing P/E, Vivanza Biosciences Limited ranks 11 of 169 in Pharmaceuticals — cheaper than 94% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session Vivanza Biosciences Limited moves 1.94% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by Vivanza Biosciences Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
